Literature DB >> 8976731

Multidrug resistance in ocular melanoma.

M McNamara1, M Clynes, B Dunne, R NicAmhlaoibh, W R Lee, C Barnes, S M Kennedy.   

Abstract

AIMS/
BACKGROUND: Metastatic disease in patients with ocular melanoma is resistant to chemotherapy. One of the main mechanisms of modulating multidrug resistance is the expression of the multidrug resistance gene 1 (MDR1) product (p-glycoprotein) by tumour cells. The purpose of this study was to evaluate the frequency of expression of the MDR1 gene in ocular melanoma whose primary treatment was surgical excision or enucleation.
METHODS: Twelve recent ocular melanomas were received fresh, snap frozen and cryostat sections of tumour were analysed for expression of MDR1 by immunohistochemistry using a well characterised monoclonal antibody to MDR1. Tumour explants were established in short term tissue culture from four tumours and cell blocks were examined by immunohistochemistry.
RESULTS: MDR1 expression was present in five of 12 ocular melanomas. Upregulation of protein expression was found in four cell lines established in short term culture from tumour explants. A recurrent tumour, initially treated by local excision and radioactive plaque, showed overexpression of MDR1 mRNA.
CONCLUSIONS: These results suggest that significant level of MDR1 may be intrinsically present in ocular melanomas before exposure to drugs involved in multidrug resistance, and indicate the possible importance of MDR1 in modulating chemoresistance in ocular melanoma. Chemosensitisation may be of potential value in planning adjuvant chemotherapy for patients with metastatic disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8976731      PMCID: PMC505681          DOI: 10.1136/bjo.80.11.1009

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  20 in total

1.  Multiple drug resistance-related messenger RNA expression in archival formalin-fixed paraffin-embedded human breast tumour tissue.

Authors:  L O'Driscoll; S Kennedy; E McDermott; P Kelehan; M Clynes
Journal:  Eur J Cancer       Date:  1996-01       Impact factor: 9.162

2.  Metastatic patterns of choroidal melanoma.

Authors:  L H Einhorn; M A Burgess; J A Gottlieb
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

3.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

4.  Prognosis in metastatic choroidal melanoma.

Authors:  A Y Bedikian; H Kantarjian; S E Young; G P Bodey
Journal:  South Med J       Date:  1981-05       Impact factor: 0.954

5.  Prognostic factors in choroidal and ciliary body melanomas.

Authors:  H F Shammas; F C Blodi
Journal:  Arch Ophthalmol       Date:  1977-01

6.  Prognostic implication of immunodetection of P glycoprotein in Ewing's sarcoma.

Authors:  A Roessner; Y Ueda; B Bockhorn-Dworniczak; S Blasius; A Peters; P Wuisman; J Ritter; M Paulussen; H Jürgens; W Böcker
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

7.  Survival in metastatic ocular melanoma.

Authors:  S Rajpal; R Moore; C P Karakousis
Journal:  Cancer       Date:  1983-07-15       Impact factor: 6.860

8.  Prognostic factors in malignant melanoma of the choroid: a retrospective survey of cases occurring in Northern Ireland between 1965 and 1980.

Authors:  M N Kidd; R W Lyness; C C Patterson; P B Johnston; D B Archer
Journal:  Trans Ophthalmol Soc U K       Date:  1986

Review 9.  P-glycoproteins in pathology: the multidrug resistance gene family in humans.

Authors:  R S Weinstein; J R Kuszak; L F Kluskens; J S Coon
Journal:  Hum Pathol       Date:  1990-01       Impact factor: 3.466

10.  P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies.

Authors:  G C Wishart; J A Plumb; J J Going; A M McNicol; C S McArdle; T Tsuruo; S B Kaye
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

View more
  7 in total

1.  A new mdr-1 encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections.

Authors:  E Moran; A Larkin; G Doherty; P Kelehan; S Kennedy; M Clynes
Journal:  J Clin Pathol       Date:  1997-06       Impact factor: 3.411

Review 2.  Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma.

Authors:  Kevin G Chen; Julio C Valencia; Jean-Pierre Gillet; Vincent J Hearing; Michael M Gottesman
Journal:  Pigment Cell Melanoma Res       Date:  2009-08-29       Impact factor: 4.693

3.  Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma.

Authors:  P Terheyden; E B Bröcker; J C Becker
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

4.  Resistance of uveal melanoma to the interstrand cross-linking agent mitomycin C is associated with reduced expression of CYP450R.

Authors:  P Gravells; L Hoh; D Canovas; I G Rennie; K Sisley; H E Bryant
Journal:  Br J Cancer       Date:  2011-03-08       Impact factor: 7.640

5.  Expression of P-glycoprotein in human retinoblastoma and its clinical significance.

Authors:  Sumita Sethi; Manzoor Ahmad Malik; Sandeep Goswami; Parul Saxena; Arpna Srivastava; Seema Kashyap; Neelam Pushker; Mandeep Singh Bajaj; Sameer Bakhshi; Jasbir Kaur
Journal:  Tumour Biol       Date:  2014-08-31

Review 6.  The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy.

Authors:  Chung-Pu Wu; Suresh V Ambudkar
Journal:  Acta Pharm Sin B       Date:  2014-01-13       Impact factor: 11.413

Review 7.  Membrane Transporters and Channels in Melanoma.

Authors:  Ines Böhme; Roland Schönherr; Jürgen Eberle; Anja Katrin Bosserhoff
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.